Clinical trials: Inflammatory Disorder
Ulcerative Colitis
A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice
The primary purpose of this study is to evaluate the efficacy of filgotinib in establishing clinical remission at Week 10 or 22.
- Trial name
- NCT06964113
- Testing
- Filgotinib Maleate
- Where
- 19 sites in South Korea
- Volunteers
- 94 people
- Sponsor
- Eisai Korea Inc.
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
The primary objectives of this study are to assess whether there is transfer of Certolizumab Pegol (CZP) into breast milk of lactating mothers who are receiving an established dosing regimen of CZP by evaluating the concentration…
- Conditions
- Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- CRADLE (NCT02154425)
- Testing
- Breast milk sampling, Certolizumab Pegol
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 17 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Hyperpigmentation, Post-inflammatory Hyperpigmentation
The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation
The purpose of this study is to assess the effects of Cetyl Tranexamate Mesylate on acne-related hyperpigmentation through a specific delivery form known as TeraCeutic TXVector.
- Conditions
- Hyperpigmentation, Post-inflammatory Hyperpigmentation, Acne
- Trial name
- NCT06080035
- Testing
- Topical Cetyl Tranexamate Mesylate
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Integrative Skin Science and Research
Avascular Necrosis, Osteoarthritis
Continuum™ Metal Bearing System in Total Hip Arthroplasty
The study is a multi-center, prospective, non-controlled, consecutive cohort post market surveillance study. The objective of this study is to obtain survival and outcome data on the Continuum Metal Bearing System in primary…
- Conditions
- Avascular Necrosis, Osteoarthritis, Inflammatory Arthritis, Post-traumatic; Arthrosis
- Trial name
- NCT03382652
- Testing
- Metal-on-Metal Articulation
- Where
- 3 sites in United States, Finland
- Volunteers
- 83 people
- Sponsor
- Zimmer Biomet
Colitis, Ulcerative
A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis
The purpose of this study is to assess the safety and tolerability, efficacy, and biomarker response of BMS-986165 administered orally in participants with moderate to severe ulcerative colitis.
- Trial name
- NCT04613518
- Testing
- BMS-986165
- Where
- 26 sites in United States, Australia and 6 more
- Volunteers
- 38 people
- Sponsor
- Bristol-Myers Squibb
Ulcerative Colitis
Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy
The objective of this study is to evaluate the efficacy and the tolerability of oral parnaparin sodium (210mg), administered in extended-release tablets identified as CB-01-05-MMX™.
- Trial name
- NCT00867438
- Testing
- Sigmoidoscopy
- Volunteers
- 133 people
- Sponsor
- Cosmo Technologies Ltd
Inflammatory Bowel Disease
A Retrospective Observational Study to Assess the Impact of Co-morbidities on Treatment Response in Inflammatory Bowel Disease
The purpose of this study was to evaluate the impact of the co-morbidities profile on treatment response to biological therapy in inflammatory bowel disease (IBD) participants.
- Trial name
- NCT02861118
- Testing
- No Intervention
- Where
- 23 sites in Spain
- Volunteers
- 310 people
- Sponsor
- Takeda
Rheumatoid Arthritis
Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis
CC-292 is an oral agent that is under clinical development for the treatment of rheumatoid arthritis an autoimmune inflammatory disorder.
- Trial name
- NCT01975610
- Testing
- CC-292
- Where
- 27 sites in United States
- Volunteers
- 47 people
- Sponsor
- Celgene
Inflammatory Bowel Diseases (IBD)
BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)
This is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with relapsed and/or refractory…
- Trial name
- NCT07544160
- Testing
- ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- iCell Gene Therapeutics
Crohn's Disease
A Study of SL-325 in Crohn's Disease Patients
The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with moderate to severely active Crohn's disease.
- Trial name
- RECEPTIVE-CD1 (NCT07753850)
- Testing
- SL-325
- Where
- 20 sites in United States
- Volunteers
- 232 people
- Sponsor
- Shattuck Labs, Inc.
IBD (Inflammatory Bowel Disease)
A Phase I Study of INT-210 Capsules in Healthy Adult Subjects (INT-210-I101)
A Phase Ⅰ, Single and Multiple Ascending Dose escalation, and Food-Effect Study of the Safety, Tolerability and Pharmacokinetics of INT-210 Capsules in Healthy Adult Voluteers.
- Trial name
- INT-210-I101 (NCT07616791)
- Testing
- INT-210 Capsule
- Where
- China
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Innatus Therapeutics (Shanghai) Co., Ltd.
Colitis, Ulcerative
A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants
This is a 3-part First Time in Human (FTIH) study to evaluate the safety, tolerability, and pharmacokinetics (PK) profile of GSK4381406 following administration of single ascending doses (Part 1), repeat ascending doses (Part 2)…
- Trial name
- NCT05999708
- Testing
- GSK4381406, Indomethacin
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bacteremia, Septicemia
Diagnosis of Bacteremia/Septicemia and Culture Negative Endocarditis by the Karius Sequencing-Based Infectious Disease Diagnostic Assay
Prospective study at Duke University Hospital comparing the Karius Infectious Disease Diagnostic Sequencing Assay to blood culture results in admitted patients with bacteremia/septicemia.
- Trial name
- NCT02988414
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Karius, Inc.
Acne Vulgaris
Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris
The primary objectives of the study is to show CD2475/101 40mg tablets taken once a day for 16 weeks is superior to the placebo in Change from baseline to Week 16(Last Observation Carry Forward, Intent To Treat) in inflammatory…
- Trial name
- NCT01320033
- Testing
- CD2475/101 40 mg, Doxycycline 100 mg
- Where
- 31 sites in United States
- Volunteers
- 662 people
- Sponsor
- Galderma R&D
Crohn Disease, Plaque Psoriasis
ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar
ROLL'YN-UST is a real-life study, which includes patients in clinical remission for at least 3 months and who have been treated with a reference biotherapy for at least 6 months, and for whom the physician has decided…
- Trial name
- ROLL'YN-UST (NCT06997055)
- Testing
- Ustekinumab 45 mg, Ustekinumab 90 mg
- Where
- France
- Volunteers
- 225 people
- Sponsor
- Celltrion HealthCare France
Crohn's Disease
A Study of TRK-170 for the Treatment of Crohn's Disease
In Crohn's Disease Patients To evaluate the efficacy of TRK-170 To evaluate the PK characteristics of TRK-170 To assess the safety of TRK-170
- Trial name
- NCT01345799
- Testing
- TRK-170
- Where
- 13 sites in Belgium, Bulgaria and 11 more
- Volunteers
- 123 people
- Sponsor
- Toray Industries, Inc
Ulcerative Colitis
A Prospective Non-interventional Multicenter Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice
This is a prospective, single country, multi-center study in participants with ulcerative colitis (UC) treated with adalimumab. Up to 147 participants are enrolled at approximately 20 sites.
- Trial name
- EUREKA (NCT02499263)
- Where
- 19 sites in South Korea
- Volunteers
- 150 people
- Sponsor
- AbbVie
Chronic Obstructive Pulmonary Disease
A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD
The purpose of this study is to evaluate the dose-response relationship of different doses of CHF6001 and to identify the optimal dose (s) in terms of benefit/risk ratio for further development in the target patient population.
- Trial name
- PIONEER (NCT02986321)
- Testing
- CHF6001, Budesonide
- Volunteers
- 1,130 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Ulcerative Colitis, Colitis, Ulcerative
VE202 in Patients With Mild-to-Moderate Ulcerative Colitis
A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).
- Trial name
- NCT05370885
- Testing
- VE202, Vancomycin Oral Capsule
- Where
- 49 sites in United States, Australia and 8 more
- Volunteers
- 114 people
- Sponsor
- Vedanta Biosciences, Inc.
Ulcerative Colitis
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).This study will evaluate how safe and effective risankizumab is…
- Trial name
- REVAMP (NCT06880744)
- Testing
- Risankizumab, Vedolizumab
- Where
- 270 sites in United States, Austria and 29 more
- Volunteers
- 573 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.